Secondary hyperparathyroidism and vitamin D hormone replacement therapy: New treatment perspectives

被引：0

作者：

Gilbreath, A ^{[1
]}

机构：

[1] Bone Care Int, Madison, WI USA

来源：

DIALYSIS & TRANSPLANTATION | 2001年 / 30卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

引用

页码：109 / +

页数：4

共 19 条

[1]

*ABB LAB, 1998, ZEMPL PACK INS

[2]

[Anonymous], USRDS 1998 ANN DAT R

[3] Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].

Block, GA ;

Port, FK .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237

[4]

*BON CAR INT, 2000, HECT INJ PACK INS

[5]

*BON CAR INT, 2000, HECT PROD MON

[6] Effects of excess PTH on nonclassical target organs [J].

Bro, S ;

Olgaard, K .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (05) :606-620

[7] Intermittent doxercalciferol (1α-hydroxyvitamin D2) therapy for secondary hyperparathyroidism [J].

Frazao, JM ;

Elangovan, L ;

Maung, HM ;

Chesney, RW ;

Acchiardo, SR ;

Bower, JD ;

Kelley, BJ ;

Rodriguez, HJ ;

Norris, KC ;

Robertson, JA ;

Levine, BS ;

Goodman, WG ;

Gentile, D ;

Mazess, RB ;

Kyllo, DM ;

Douglass, LL ;

Bishop, CW ;

Coburn, JW .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (03) :550-561

[8]

Fukagawa M, 1996, J NEPHROL, V9, P219

[9]

Galbraith Susan C., 1993, P159

[10]

GOODMAN WG, 1992, ANNU REV MED, V43, P227

← 1 2 →